MR-guided prostate biopsy for planning of focal salvage after radiation therapy

Radiology

Volumn 274, Issue 1, 2015, Pages 181-191

  Ménard, Cynthia ^a,b   Iupati, Douglas ^a,b,c   Publicover, Julia ^a   Lee, Jenny ^a   Abed, Jessamine ^a   O'Leary, Gerald ^d   Simeonov, Anna ^a,b   Foltz, Warren D ^a   Milosevic, Michael ^a,b   Catton, Charles ^a,b   Morton, Gerard ^b,e   Bristow, Robert ^a,b   Bayley, Andrew ^a,b   Atenafu, Eshetu G ^a   Evans, Andrew J ^d   Jaffray, David A ^a,b   Chung, Peter ^a,b   Brock, Kristy K ^a,b   Haider, Masoom A ^d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WELLINGTON HOSPITAL   (New Zealand)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORE BIOPSY NEEDLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUID RESUSCITATION; GLEASON SCORE; HEART INFARCTION; HEMATURIA; HUMAN; HUMAN TISSUE; HYPOTENSION; LITHOTOMY POSITION; LUNG EMBOLISM; MAGNETIC RESONANCE GUIDED PROSTATE BIOPSY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PERINEAL PAIN; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REPRODUCIBILITY; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; VISUAL ANALOG SCALE; BLOOD; CANCER GRADING; CANCER STAGING; COMPUTER ASSISTED DIAGNOSIS; IMAGE GUIDED BIOPSY; LIFE EXPECTANCY; MIDDLE AGED; PATHOLOGY; PATIENT CARE PLANNING; PREDICTIVE VALUE; PROSTATIC NEOPLASMS; RISK FACTOR; VERY ELDERLY;

PROSTATE SPECIFIC ANTIGEN;

AGED; AGED, 80 AND OVER; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGE-GUIDED BIOPSY; LIFE EXPECTANCY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PATIENT CARE PLANNING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY;

EID: 84919742754     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14122681     Document Type: Article

References (48)

1. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8(2): 162-200.
2. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radition therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280(11): 969-974.
3. Edge SB, Bird DR, Compton CC, et al, eds. Prostate. In: AJCC cancer staging manual. 7th ed. New York, NY: Springer, 2010; 457-468.
4. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000; 18(19): 3352-3359.
5. Chopra S, Toi A, Taback N, et al. Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82(3): e441-e448.
6. Pucar D, Hricak H, Shukla-Dave A, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 2007; 69(1): 62-69.
7. Westphalen AC, Koff WJ, Coakley F V, et al. Prostate cancer: prediction of biochemical failure after external-beam radiation ther-apy-Kattan nomogram and endorectal MR imaging estimation of tumor volume. Radiology 2011; 261(2): 477-486.
8. Pisters LL, Leibovici D, Blute M, et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009; 182(2): 517-525;discussion 525-527
9. Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 77(5): 1338-1344.
10. Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007; 67(4): 1106-1112.
11. Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 2007; 100(4): 760-764.
12. Heidenreich A, Richter S, Thüer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 2010; 57(3): 437-443.
13. Nguyen PL, Chen MH, D'Amico AV, et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 2007; 110(7): 1485-1492.
14. Arumainayagam N, Kumaar S, Ahmed HU, et al. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int 2010; 106(7): 991-997.
15. Rouvière O. MR assessment of recurrent prostate cancer after radiation therapy. Radiology 2007; 242(2): 635-636; author reply 636-637.
16. Rouvière O, Valette O, Grivolat S, et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor-correlation with biopsy findings. Urology 2004; 63(5): 922-927.
17. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70(2): 425-430.
18. Akin O, Gultekin DH, Vargas HA, et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 2011; 21(9): 1970-1978.
19. Morgan VA, Riches SF, Giles S, Dearnaley D, de Souza NM. Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. AJR Am J Roentgenol 2012; 198(3): 596-602.
20. Westphalen AC, Reed GD, Vinh PP, Sotto C, Vigneron DB, Kurhanewicz J. Multipa-rametric 3T endorectal mri after external beam radiation therapy for prostate cancer. J Magn Reson Imaging 2012; 36(2): 430-437.
21. Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparamet-ric magnetic resonance imaging. J Urol 2011; 186(4): 1281-1285.
22. Arsov C, Quentin M, Rabenalt R, Antoch G, Albers P, Blondin D. Repeat transrectal ultrasound biopsies with additional targeted cores according to results of functional prostate MRI detects high-risk prostate cancer in patients with previous negative biopsy and increased PSA: a pilot study. Anticancer Res 2012; 32(3): 1087-1092.
23. Makni N, Puech P, Colin P, Azzouzi A, Mordon S, Betrouni N. Elastic image registration for guiding focal laser ablation of prostate cancer: preliminary results. Comput Methods Programs Biomed 2012; 108(1): 213-223.
24. Ukimura O, Desai MM, Palmer S, et al. 3-Di-mensional elastic registration system of prostate biopsy location by real-time 3-dimen-sional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol 2012; 187(3): 1080-1086.
25. Natarajan S, Marks LS, Margolis DJ, et al. Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol 2011; 29(3): 334-342.
26. Susil RC, Camphausen K, Choyke P, et al. System for prostate brachytherapy and biopsy in a standard 1.5 T MRI scanner. Magn Reson Med 2004; 52(3): 683-687.
27. Ménard C, Susil RC, Choyke P, et al. MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. Int J Radiat Oncol Biol Phys 2004; 59(5): 1414-1423.
28. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37(5): 1035-1041.
29. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6): 649-655.
30. Yoo TS, Ackerman MJ, Lorensen WE, et al. Engineering and algorithm design for an image processing Api: a technical report on ITK - the Insight Toolkit. Stud Health Technol Inform 2002; 85: 586-592.
31. Fitzpatrick JM, West JB, Maurer CR Jr Predicting error in rigid-body point-based registration. IEEE Trans Med Imaging 1998; 17(5): 694-702.
32. Evans AJ, Ryan P, Van derKwast T. Treatment effects in the prostate including those associated with traditional and emerging therapies. Adv Anat Pathol 2011; 18(4): 281-293.
33. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? results for 498 patients. Int J Radiat Oncol Biol Phys 2000; 48(2): 355-367.
34. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44(3): 837-845.
35. Cheng L, Cheville JC, Bostwick DG. Diagnosis of prostate cancer in needle biopsies after radiation therapy. Am J Surg Pathol 1999; 23(10): 1173-1183.
36. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164(2): 400-404.
37. Kim CK, Park BK, Lee HM. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 2009; 29(2): 391-397.
38. Groenendaal G, Moman MR, Korporaal JG, et al. Validation of functional imaging with pathology for tumor delineation in the prostate. Radiother Oncol 2010; 94(2): 145-150.
39. Langer DL, van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 2008; 249(3): 900-908.
40. Mazaheri Y, Hricak H, Fine S W, et al. Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology 2009; 252(2): 449-457.
41. Vargas HA, Akin O, Franiel T, et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011; 259(3): 775-784.
42. Moman MR, van den Berg CA, Boeken Kruger AE, et al. Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. Int J Radiat Oncol Biol Phys 2010; 76(3): 741-746.
43. Singh AK, Guion P, Sears-Crouse N, et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-pros-tatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol 2007; 2: 36.
44. Fonteyne V, Villeirs G, Speleers B, et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intrapros-tatic lesion. Int J Radiat Oncol Biol Phys 2008; 72(3): 799-807.
45. Miralbell R, Mollà M, Rouzaud M, et al. Hypofractionated boost to the dominant tumor region with intensity modulated ste-reotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study. Int J Radiat Oncol Biol Phys 2010; 78(1): 50-57.
46. Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised unifocal and mul-tifocal prostate cancer: a prospective development study. Lancet Oncol 2012; 13(6): 622-632.
47. Bahn D, de Castro Abreu AL, Gill IS, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012; 62(1): 55-63.
48. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22(4): 746-757.